Diagnostic value and clinical significance of circulating miR‑650 and CA211 in detecting of gastric carcinoma

Abstract

The present study determined the levels of plasma biomarkers in patients with gastric carcinoma (GC) and investigated their clinical significance and diagnostic value. Between April 2014 and December 2018, 90 patients with GC, 90 patients with precancerous lesions (Pre) and 45 healthy controls (NC) were recruited from the Affiliated Liutie Central Hospital of Guangxi Medical University. Five markers were measured: microRNA-650 (miRNA-650; using reverse transcription-quantitative polymerase chain reaction), and carcinoembryonic antigen (CEA), carbohydrate antigen (CA)125, CA211 and CA50 using electrochemiluminescence. Circulating markers were all upregulated in patients with GC (P<0.05), and CA211 and CA50 were significantly increased in patients with Pre. The miRNA-650 and CA211 had an area under the curve (AUC) of 0.700 (moderate) and 0.866 (high), respectively, in the diagnosis of GC. Differentiation of GC from Pre yielded an AUC of 0.665 (low) and 0.708 (moderate), respectively. The combination model of miRNA-650 and CA211 showed an appropriate value of AUC (0.887) to discriminate the GC patients from the healthy subjects with a sensitivity and specificity of 82.5 and 97.7%. Additionally, differentiating GC from Pre yielded an AUC of 0.767 with a sensitivity of 57.1% and a specificity of 95%, respectively. In terms of clinicopathological features, the expression of miRNA-650 and CA211 in plasma was not associated with the patients' age, sex, Tumor-Node-Metastasis stage, or histological type. In conclusion, plasma miRNA-650 and CA211 is a promising and powerful non-invasive marker for the detection of GC.

Efficacy of circulating microRNA‑130b and blood routine parameters in the early diagnosis of gastric cancer

“…Combinations of biomarkers, such as circulating miR-19a-3p and miR-483-5p, can enhance the diagnostic performance in various cancer types (59)(60)(61)(62). Notably, Chen et al (18) recently demonstrated that miR-650 combined with CA211 could be an effective diagnostic indicator for screening of the incidence of GC. Sun et al (63) demonstrated that the combination of serum multi-dimensional biomarkers could further improve the specificity and sensitivity of GC detection, thus achieving higher diagnostic efficiency.…”

“…A recent study has reported that the combination of miR-650 and CA211 can distinguish between benign and malignant GC ( 18 ). Therefore, we hypothesized that the combined assessment of miRNAs and blood routine parameters may reveal novel insights for the diagnosis of GC.…”

LncRNA PCGEM1 in Human Cancers: Functions, Mechanisms and Promising Clinical Utility

“…For example, it could modulate oxaliplatin resistance via the miR-129-5p/ETV1 axis in HCC, indicating a promising strategy for combating HCC chemotherapy resistance (18). Currently, endoscopy and biopsy are the standard diagnostic approaches for GC, and their utility is confined to the invasiveness of the disease and limited medical resources (84). Jiang et al (29) assessed PCGEM1 expression in GC patient serum and found that it could reflect the pathophysiological state of GC (29), demonstrating that this molecule might be a favorable indicator for GC diagnosis and prognosis.…”

“…For example, it could modulate oxaliplatin resistance via the miR-129-5p/ETV1 axis in HCC, indicating a promising strategy for combating HCC chemotherapy resistance ( 18 ). Currently, endoscopy and biopsy are the standard diagnostic approaches for GC, and their utility is confined to the invasiveness of the disease and limited medical resources ( 84 ). Jiang et al.…”

Metabolomics study identified bile acids as potential biomarkers for gastric cancer: A case control study

“…However, gastroscopy consumes tremendous medical resources, and its cost-benefit remains debatable. Besides, because of its invasiveness, gastroscopy causes great anxiety to the subjects (7,8). Therefore, current screening strategies only cover high-risk individuals who are older than 40 years or those with a prior history of gastropathy (9).…”